J07BX07 - Chikungunya Vaccines |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the Chikungunya vaccine, no porphyrinogenic effects are expected.
Chemical description
Live attenuated virus vaccine.
Therapeutic characteristics
The Chikungunya vaccine is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | European Medicines Agency (EMA). SmPC Ixchiq.
|
|
| 2. | Norwegian institute of public health. Vaccines and vaccination.
|
|
Tradenames
Ixchiq 
Ixchiq 
Vaccines